This might be provided in the ongoing DESTINY-Gastric03 (NCT04379596) and EPOC2203 (jRCT2031230477) studies, which evaluated T-DXd combinations for HER2-low gastric cancer. This evidence concerns the gene ERBB2 and gastric cancer.